Parkinson's disease

@article{Samii2004ParkinsonsD,
  title={Parkinson's disease},
  author={Ali Samii and John G. Nutt and Bruce R. Ransom},
  journal={The Lancet},
  year={2004},
  volume={363},
  pages={1783-1793}
}
Parkinson's disease is the most common serious movement disorder in the world, affecting about 1% of adults older than 60 years. The disease is attributed to selective loss of neurons in the substantia nigra, and its cause is enigmatic in most individuals. Symptoms of Parkinson's disease respond in varying degrees to drugs, and surgery offers hope for patients no longer adequately controlled in this manner. The high prevalence of the disease, and important advances in its management, mean that… Expand
PARKINSON ’ S DISEASE
Parkinson's disease is the second most common neurodegenerative disease (1) and the most common movement disorder other than the essential tremor. It was first described by James Parkinson in 1817 inExpand
Parkinson's disease: Therapeutic options
TLDR
This paper examines, step by step, the different treatment options for Parkinson’s disease by following the criteria for therapy aimed at maximum benefits with minimal side effects in the short and long term. Expand
Olfactory dysfunction in Parkinson's disease
Olfactory dysfunction in Parkinson's disease (PD) has been described for more than thirty years and known as one of the commonest non-motor symptoms in PD. Recently, it attracts widespread attentionExpand
[The role of estrogens in Parkinson's disease].
TLDR
Agents which influence neurodegenerative processes of the extrapyramidal system based on available literature concerning clinical trials in Parkinson's disease are reviewed and special attention is paid to the potential role of estrogens as agents modulating the risk of PD occurrence and their neuroprotective action. Expand
Potential of the Rotigotine Transdermal Patch for Patients with Advanced Parkinson's Disease
The symptomatic burden of Parkinson’s disease (PD) can be managed effectively for long periods, although no disease-modifying treatments have been developed. The clinical diagnosis of PD is based onExpand
Young Onset Parkinson’s Disease: A Modern and Tailored Approach
TLDR
People with YOPD tend to have different family and societal engagements compared to those with late-onset PD, and these unique features have implications for clinical management, and call for a tailored multidisplinary approach involving shared-decision making. Expand
Chapter 50 Pain in Parkinson's disease.
TLDR
The chapter explores that several animal studies have demonstrated the involvement of the basal ganglia and dopamine as a transmitter in pain and nociceptive pathways, and there is also evidence for alterations in central pain processing in PD patients. Expand
Vortioxetine Improved Depressive State In Parkinson’s Disease
TLDR
The case of a 67-year-old Japanese Parkinson’s disease patient with depression who was successfully treated with vortioxetine, which improved her depressive state without worsening PD. Expand
3 CSF Biomarkers in Parkinson ’ s Disease 1
TLDR
Great attention has been drawn to non-motor symptoms of Parkinson’s disease, namely cognitive decline, behavioural changes, sleep disorders and autonomic dysfunction, due to their relevant impact on quality of life of parkinsonian patients. Expand
Surgical Insights into Parkinson's Disease
Surgery for Parkinson's disease was popularized in the mid-twentieth century before the advent of effective medical therapies. Early lesioning treatments contributed to our understanding of theExpand
...
1
2
3
4
5
...